Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon

Journal of Neuroimmunology

Volumn 20, Issue 1, 1988, Pages 15-23

  Kastrukoff, Lorne F ^a   Morgan, Norma G ^a   Aziz, Terry M ^a   Zecchini, Daniel ^a   Berkowitz, Jonathan ^b   Paty, Donald W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Statistical Consultant   (Canada)

Author keywords

Lymphoblastoid interferon; Natural killer cell

Indexed keywords

ALPHAN1 INTERFERON; INTERFERON;

ADULT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CHRONIC DISEASE; DISEASE; FEMALE; HUMAN; INTERFERON TYPE I; KILLER CELLS, NATURAL; MALE; MIDDLE AGE; MULTIPLE SCLEROSIS; PHENOTYPE; REFERENCE VALUES; SUPPORT, NON-U.S. GOV'T;

EID: 0023816662     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-5728(88)90109-9     Document Type: Article

References (37)

1. Dysfunction of natural killer cells in multiple sclerosis, a possible pathogenetic factor
2. Interferon and the immune system
3. Separation of leucocytes from blood and bone marrow
4. Immunological parameters in multiple sclerosis patients with special reference to the herpes virus group
5. Natural killer cell activity in multiple sclerosis
6. Significance of natural killer cells in cancer research
7. Natural killer cells: their role in defences against disease
8. The effect of recombinant alpha-interferon on defective natural killer cell activity in multiple sclerosis
9. 2
10. Recent advances in the study of interferon
11. The significance of abnormal immune responses in patients with multiple sclerosis
12. Virus interference I The interferons
13. Intrathecal interferon reduces exacerbations of multiple sclerosis
14. Intrathecal interferon in multiple sclerosis
15. Systemic alpha-interferon therapy of multiple sclerosis
16. Subpopulations of human natural killer cells defined by expression of the Leu 7 (HNK-1) and Leu 11 (NK-15) antigens
17. Multiple sclerosis
18. Multiple sclerosis
19. Decreased natural killer cell killing in patients with multiple sclerosis — An analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to disease activity
20. Absence of virus-induced lymphocyte suppressor and interferon production in multiple sclerosis
21. Interferon responses of leukocytes
22. Interferon and natural killer cell activity of human peripheral blood mononuclear cells in vitro: multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis
23. Immunology of MS
24. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity
25. Genetic and functional diversity of interferons in man
26. Natural killer cell activity in patients with multiple sclerosis given interferon
27. PPD, PWM and PHA-induced interferon in stable multiple sclerosis: association with HLA-DW2 antigen and clinical variables
28. Defective production of interferon associated with HLA-DW2 antigen in stable multiple sclerosis
29. Cell mediated cytotoxicity against virus infected target cells in humans. II. Interferon induction and activation of natural killer cells
30. Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis
31. Problems of experimental trials of therapy in multiple sclerosis: report by the Panel on Evaluation of Experimental Trials of Therapy in Multiple Sclerosis
32. Lack of correlation between interferon production and natural killer activity of lymphocytes in multiple sclerosis
33. Analysis by a single cell cytotoxicity assay of natural killer (NK) cell frequencies among human large granular lymphocytes and of the effects of interferon on their activity
34. Interferon production by lymphocytes from multiple sclerosis and non-MS patients
35. Interferon-induced NK augmentation in humans. An analysis of target recognition, effector cell recruitment and effector cell recycling
36. Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients
37. Natural killing activity and interferon production in multiple sclerosis